Pacira Pharma (PCRX) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
August 2, 2017 7:30 AM EDT-- EXPAREL® Net Product Sales Up 6% Year-Over-Year ---- Full-year EXPAREL net product sales guidance of $290 to $310 million reiterated ---- Conference Call Today at 8:30 a.m. ET --
PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017.
We are pleased to... More
